SPHS - Sophiris Bio, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.67
+0.01 (+0.38%)
At close: 4:00PM EDT

2.65 -0.02 (-0.75%)
After hours: 5:20PM EDT

Stock chart is not supported by your current browser
Previous Close2.66
Open2.70
Bid2.55 x 1000
Ask2.65 x 800
Day's Range2.55 - 2.70
52 Week Range1.80 - 4.05
Volume240,385
Avg. Volume524,332
Market Cap111.988M
Beta0.22
PE Ratio (TTM)N/A
EPS (TTM)-0.53
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • Sophiris Bio Extends the Interest Only Period under its Loan and Security Agreement
    PR Newswire8 days ago

    Sophiris Bio Extends the Interest Only Period under its Loan and Security Agreement

    SAN DIEGO and VANCOUVER, British Columbia, Sept. 14, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that it has met the requirements within its existing loan and security agreement with Silicon Valley Bank ("SVB") to extend the interest only periods between September 30, 2018 and March 31, 2019. The Company will begin making interest and principal payments starting on April 1, 2019 and ending on the final payment date of September 1, 2021. The extension of this interest only period allows the Company to shift principal payments of $1.2 million, which would have been due during the periods between September 30, 2018 and March 31, 2019, to periods after April 1, 2019.

  • Zacks Small Cap Research22 days ago

    SPHS: Patient Death in Phase 2b Trial Unlikely Related to Topsalysin Treatment…

    On August 29, 2018, Sophiris Bio, Inc. (SPHS) announced the result of an investigation into the previously announced patient death in the ongoing Phase 2b trial of topsalysin (PRX302) in localized clinically significant prostate cancer. After reviewing the autopsy report, hospital records, and hypersensitivity tests, it was determined that the patient’s death was unlikely the result of topsalysin or the procedure. The official cause of death listed on the autopsy report is Sudden Cardiac Deach (SCD) probably due to arrhythmia and the patient had a number of risk factors for SCD.

  • ACCESSWIRE23 days ago

    Today’s Research Reports on Stocks to Watch: Opiant Pharmaceuticals and Sophiris Bio

    NEW YORK, NY / ACCESSWIRE / August 30, 2018 / Shares of Opiant saw big gains after Wall Street learned that Emergent Biosciences Inc. announced the acquisition of Adapt Pharma® for $635 million. Adapt markets NARCAN® Nasal Spray for the treatment of opioid overdose, for which Opiant Pharmaceuticals, Inc. receives tiered royalties. Shares of Sophiris Bio also saw big gains after announcing updates on a phase 2b Localized Prostate Cancer Trial.

  • Sophiris Bio to Present at the H.C. Wainwright 20th Annual Global Investment Conference
    PR Newswire23 days ago

    Sophiris Bio to Present at the H.C. Wainwright 20th Annual Global Investment Conference

    SAN DIEGO and VANCOUVER, British Columbia , Aug. 29, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

  • Sophiris Bio Updates on Phase 2b Localized Prostate Cancer Trial
    PR Newswire24 days ago

    Sophiris Bio Updates on Phase 2b Localized Prostate Cancer Trial

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 29, 2018 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced the conclusion of the ongoing investigation into the previously reported death of a patient in the Company's Phase 2b trial for the treatment of localized prostate cancer is unlikely to be related to either topsalysin or the procedure. The regulatory authorities in the United States and the United Kingdom where the study is being conducted have been notified. Following a comprehensive review of the recently received autopsy report, together with hospital records and the negative serology results for acute hypersensitivity, the Investigator and Company believe that the cause of death is consistent with the autopsy finding of Sudden Cardiac Death (SCD) probably due to an arrhythmia.

  • Zacks Small Cap Researchlast month

    SPHS: Ready to Advance Topsalysin into Registration Studies…

    A total of 38 patients received a single administration of topsalysin to treat a clinically significant tumor, which was defined for this study as either a Gleason score of 6 (pattern 3 + 3) and greater than or equal to 6 mm maximum cancer core length (MMCL), or a Gleason score of 7 (pattern 3 + 4) and less than or equal to 10 mm MCCL. Six months following administration of topsalysin each patient received a follow-up biopsy.

  • Sophiris Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
    PR Newswirelast month

    Sophiris Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

    SAN DIEGO and VANCOUVER, British Columbia , Aug. 14, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

  • Zacks Small Cap Research2 months ago

    SPHS: Interim Data Reported for P2b Study of Topsalysin in Localized Prostate Cancer

    A total of 38 patients received a single administration of topsalysin to treat a clinically significant tumor, which was defined for this study as either a Gleason score of 6 (pattern 3 + 3) and greater than or equal to 6 mm maximum cancer core length (MMCL), or a Gleason score of 7 (pattern 3 + 4) and less than or equal to 10 mm MCCL. Six months following administration of topsalysin each patient received a follow-up biopsy.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Sophiris

    NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Spectrum Pharmaceuticals saw its shares rise after a Bloomberg report revealed that the hematology and oncology company may be considering a sale. Shares of Sophiris Bio were bouncing in Tuesday trading after plummeting on Monday when Wall Street learned that a patient had died in the company’s ongoing phase 2b clinical trial for its prostate drug topsalysin. Spectrum Pharmaceuticals, Inc. shares closed up 14.59% on about 6.4 million shares traded yesterday.

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: Sophiris Bio and Achaogen

    NEW YORK, NY / ACESSWIRE / June 26, 2018 / U.S. equities plunged on Monday, as indexes posted their biggest one-day decline in week, as fresh threats from President Trump added to the uncertainties of ...

  • MarketWatch3 months ago

    Sophiris Bio shares plummet 46% on news of patient death in trial for prostate cancer drug

    Sophiris Bio Inc. (sphs) shares plummeted nearly 46% in premarket trade on Monday after the company said that a patient had died in the company's ongoing phase 2b clinical trial for its prostate cancer drug topsalysin. The patient death happened the same day that the patient was administered the drug for the second time, the company said.

  • PR Newswire3 months ago

    Sophiris Bio Reports Top-Line Interim Safety and Biopsy Findings For its Phase 2b Clinical Trial of Topsalysin in Localized Prostate Cancer

    A single administration of topsalysin continues to demonstrate an ability to ablate targeted prostate cancer cells with 10 of 35 patients (29%) demonstrating a clinical response of which 6 patients had a complete ablation with no detectable cancer on targeted biopsy of the treated area. Separately, Sophiris was recently notified that a patient death occurred on the same day as their second administration.

  • Want To Invest In Sophiris Bio Inc (NASDAQ:SPHS)? Here’s How It Performed Lately
    Simply Wall St.3 months ago

    Want To Invest In Sophiris Bio Inc (NASDAQ:SPHS)? Here’s How It Performed Lately

    Increase in profitability and industry-beating performance can be essential considerations in a stock for some investors. In this article, I will take a look at Sophiris Bio Inc’s (NASDAQ:SPHS) trackRead More...

  • Zacks Small Cap Research4 months ago

    SPHS: Countdown to Release of Topline Data for Phase 2b Study of Topsalysin in Prostate Cancer at end of 2Q18

    Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. The compound has been successfully tested in one Phase 3 clinical trial for BPH and a Phase 2a clinical trial for localized prostate cancer.

  • Benzinga4 months ago

    Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 15) Inspire Medical Systems Inc (NYSE: INSP ) Aptevo Therapeutics ...

  • Sophiris Bio Reports First Quarter 2018 Financial Results and Key Corporate Highlights
    PR Newswire4 months ago

    Sophiris Bio Reports First Quarter 2018 Financial Results and Key Corporate Highlights

    SAN DIEGO and VANCOUVER, British Columbia , May 14, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

  • Loss-Making Sophiris Bio Inc (NASDAQ:SPHS) Expected To Breakeven
    Simply Wall St.5 months ago

    Loss-Making Sophiris Bio Inc (NASDAQ:SPHS) Expected To Breakeven

    Sophiris Bio Inc’s (NASDAQ:SPHS): Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The US$85.49M market-cap company announced a latestRead More...

  • Zacks Small Cap Research6 months ago

    SPHS: Topline Results from Phase 2b Study of Topsalysin at end of 2Q18

    Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. Sophiris is currently conducting a Phase 2b clinical trial of topsalysin in patients with localized clinically significant prostate cancer (NCT03081481).

  • Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial Results and Key Corporate Highlights
    PR Newswire6 months ago

    Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial Results and Key Corporate Highlights

    SAN DIEGO and VANCOUVER, British Columbia , March 21, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

  • Sophiris Bio to Present at 17th Annual Needham Healthcare Conference
    PR Newswire6 months ago

    Sophiris Bio to Present at 17th Annual Needham Healthcare Conference

    SAN DIEGO and VANCOUVER, British Columbia , March 15, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

  • Sophiris Bio to Participate in the 10th Annual Biotech Showcase Conference
    PR Newswire9 months ago

    Sophiris Bio to Participate in the 10th Annual Biotech Showcase Conference

    SAN DIEGO and VANCOUVER, British Columbia , Dec. 27, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

  • Sophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate Cancer
    PR Newswire9 months ago

    Sophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate Cancer

    SAN DIEGO and VANCOUVER, British Columbia, Dec. 11, 2017 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris") today announced that it has completed enrollment in its Phase 2b study to evaluate the safety and tolerability of topsalysin in treating men with clinically significant localized prostate cancer. "I am delighted that Sophiris has completed enrollment into its multi-center Phase 2b study. My thanks to the men and my colleagues in each clinical trial center for recognizing the potential of topsalysin to focally treat localized, clinically significant prostate cancer with a minimally invasive, targeted, short duration procedure," said Professor Hashim Ahmed, Chair of Urology, Imperial College London & Imperial College Healthcare NHS Trust and an investigator in the study.

  • Sophiris Bio to Participate in the 29th Annual Piper Jaffray Healthcare Conference
    PR Newswire10 months ago

    Sophiris Bio to Participate in the 29th Annual Piper Jaffray Healthcare Conference

    SAN DIEGO and VANCOUVER, British Columbia , Nov. 27, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

  • Is Sophiris Bio Inc’s (SPHS) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.10 months ago

    Is Sophiris Bio Inc’s (SPHS) Balance Sheet Strong Enough To Weather A Storm?

    While small-cap stocks, such as Sophiris Bio Inc (NASDAQ:SPHS) with its market cap of USD $61.57M, are popular for their explosive growth, investors should also be aware of their balanceRead More...

  • SPHS: First Dosing in Phase 2b Trial of Topsalysin in Prostate Cancer Almost Complete; Data in 1H18
    Zacks Small Cap Research10 months ago

    SPHS: First Dosing in Phase 2b Trial of Topsalysin in Prostate Cancer Almost Complete; Data in 1H18

    As expected, the company did not report any revenues during the quarter. The company reported a net loss of $2.7 million, or $0.09 per share. The increase was due to costs associated with the Phase 2b trial of topsalysin in prostate cancer along with increased manufacturing costs.